Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month High - Here's Why

Key Points

• Regeneron shares reached a new 52-week high, rising 3.2% intraday to approximately $849.93, supported by strong momentum and a “Moderate Buy” analyst consensus.
• The company reported strong quarterly results, with EPS of $14.29 and revenue of $4.29 billion, exceeding estimates; revenue increased 16.7% year over year. Regeneron also declared a quarterly dividend of $0.94 per share.
• Legal and pipeline risks remain: securities lawsuits allege investors were misled about risks tied to the fianlimab-Libtayo melanoma trial, while analysts have issued mixed price-target revisions despite continued optimism around Regeneron’s drug pipeline.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $849.93 and last traded at $847.1380, with a volume of 277201 shares. The stock had previously closed at $823.82.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sector outperformance and favorable outlook: Regeneron has outpaced the healthcare sector, while analysts remain moderately optimistic about its prospects. The stock is trading well above its 50-day and 200-day moving averages, indicating strong recent momentum. Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
• Positive Sentiment: Long-term complement-inhibitor opportunity: A new market report projects substantial growth in the global complement-inhibitors market through 2035 and lists Regeneron among the leading participants. This supports the company’s longer-term pipeline and commercial opportunity, though the report does not announce a specific new Regeneron product or financial forecast. 2026 Complement Inhibitors Market Analysis Report
• Neutral Sentiment: Continued demand for Libtayo: Regeneron is identified as a key player in the expanding non-melanoma skin-cancer treatment market, where Libtayo is an approved therapy. The industry growth outlook is constructive, but the article provides no new sales, approval, or guidance information for Regeneron. Non-Melanoma Skin Cancer Market Report
• Negative Sentiment: Multiple securities lawsuits increase risk: Several law firms announced or promoted class actions against Regeneron on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026. The complaints allege that Regeneron and executives misrepresented risks surrounding the Phase III fianlimab-Libtayo melanoma trial, including slowing event accrual, clinical differentiation, and a late protocol amendment. The allegations have not been proven, but the litigation could increase legal costs, reputational risk, and uncertainty around the drug’s growth prospects. Investors have until September 14, 2026, to seek lead-plaintiff status. Regeneron Class Action Announcement

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on REGN shares. JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating on the stock in a research report on Monday, May 18th. Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. HSBC cut their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating on the stock in a research report on Monday, July 6th. Truist Financial upped their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Finally, BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a research note on Monday, May 18th. Fourteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $800.36.

Regeneron Pharmaceuticals Trading Up 3.2%

The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $87.53 billion, a PE ratio of 20.99, a PEG ratio of 1.36 and a beta of 0.19. The business's 50-day moving average is $725.36 and its two-hundred day moving average is $718.57.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the company posted $12.81 earnings per share. The business's quarterly revenue was up 16.7% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.29%.

Insiders Place Their Bets

In other news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director directly owned 1,703 shares of the company's stock, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock valued at $1,090,030 over the last quarter. Company insiders own 6.97% of the company's stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Orbimed Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter worth about $11,358,000. Lockheed Martin Investment Management Co. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at about $2,702,000. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $5,682,636,000. National Pension Service boosted its holdings in Regeneron Pharmaceuticals by 29.8% in the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company's stock valued at $278,636,000 after purchasing an additional 82,853 shares in the last quarter. Finally, Eurizon Capital SGR S.p.A. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $10,472,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source